Ramtin Agah - Jul 1, 2025 Form 4 Insider Report for RenovoRx, Inc. (RNXT)

Role: Chief Medical Officer, Director
Signature: /s/ Ramtin Agah
Stock symbol: RNXT
Transactions as of: Jul 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 7/3/2025, 04:45 PM
Previous filing: Jun 9, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Agah Ramtin	Chief Medical Officer, Director	C/O RENOVORX, INC., 2570 W EL CAMINO REAL, SUITE 320, MOUNTAIN VIEW	/s/ Ramtin Agah	2025-07-03	0001862617

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNXT	Stock Option	Award	$0	+63.6K		$0.00	63.6K	Jul 1, 2025	Common stock	63.6K	$1.27	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of 63,636 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

Content

Represents an award of 63,636 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.